Wave Life Sciences Ltd. (WVE)
After hours:
| Previous close | 4.7400 |
| Open | 4.8000 |
| Bid | 4.6400 x 100 |
| Ask | 4.7000 x 100 |
| Day's range | 4.6400 - 4.8100 |
| 52-week range | 3.1500 - 7.6700 |
| Volume | |
| Avg. volume | 890,476 |
| Market cap | 569.843M |
| Beta (5Y monthly) | -1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave’s next generation GalNAc-siRNA format with potential for best-in-class potency and durability GSK collaboration continues to span all Wave modalities, including RNA editing, with target validation ongoing in multiple therapy areas Wave is on track to initiate a clinical trial of its wholly owned INHBE program for obesity
- GlobeNewswire
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in April. Cantor Virtual Muscular Dystrophy Symposium Date: Wednesday, April 3, 2024Analyst-led fireside chat presentation time: 3:10 p.m.
- GlobeNewswire
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable silencing, weight loss with no loss of muscle mass, reduction of visceral fat, and every-six-month or annual subcutaneous dosing; clinical trial initiation expected 1Q 2025 Dose escalation ongoing in RestorAATion-1 clinical trial of WVE-006, industry’s first-ever RNA editing candidate in the clinic; GalNAc pharmacology translating as expected and proof-of-mechanism data from patients wit
